论文部分内容阅读
目的:探讨细胞角蛋白 19( C K19)作为肺癌指标的临床价值.方法:应用 CENTOCOR C Y F R A21?1 放射免疫分析药盒测定肺癌病人血清细胞角蛋白19( C K19)的数值.结果:健康人 C K19 的平均值为 0.67 NG/M L,肺腺癌(Ⅲ、Ⅳ期) C K19 的阳性率为41.7％ ,肺鳞状上皮癌(Ⅲ、Ⅳ期)为69.2％ ,大细胞肺癌为25.0％ ,小细胞肺癌为 33.3％ . C K19 比 S C C抗原具有较高的阳性率.结论: C K19 对肺鳞状上皮癌具有较高的诊断价值.“,”Objective:This paper was designed to value the clinical significance of a lung cancer marker,cytokeratin 19(CK19).Methods:With the aid of Centocor CYFRA 21 1 RIA kit, wedetected the serum CK19 in patients with lung cancer.With the aid of Centocor CYFRA 21 1 RIA kit, wedetected the serum CK19 in patients with lung cancer.Results:The mean value of CK19 in normal people was 0.67 ng/ml. The positive rate of CK19 was 41.7%, in pulmonary adenocarcinoma (Ⅲ、Ⅳ phase) 69.2% in squamous cell carcinoma(Ⅲ、Ⅳ phase),25.0% in large cell carcinoma of lung,and 33.3% in small cell carcinoma. The positive rate of CK19 was higher than that of SCC antigen. The mean value of CK19 in normal people was 0.67 ng/ml. The positive rate of CK19 was 41.7%, in pulmonary adenocarcinoma (Ⅲ、Ⅳ phase) 69.2% in squamous cell carcinoma(Ⅲ、Ⅳ phase),25.0% in large cell carcinoma of lung,and 33.3% in small cell carcinoma. The positive rate of CK19 was higher than that of SCC antigen. Conclusion:CK19 was of significantly dcagnostic value for squamous epithelioma.